Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 10 | 2018 | 30 | 2.880 |
Why?
|
| Biomarkers, Tumor | 10 | 2015 | 184 | 2.510 |
Why?
|
| Rectal Neoplasms | 5 | 2015 | 13 | 2.390 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2015 | 16 | 2.360 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 90 | 2.080 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 509 | 1.920 |
Why?
|
| Decision Support Techniques | 2 | 2023 | 46 | 1.510 |
Why?
|
| Smoking | 5 | 2023 | 165 | 1.490 |
Why?
|
| Chemoradiotherapy | 4 | 2015 | 58 | 1.150 |
Why?
|
| Disease-Free Survival | 10 | 2015 | 152 | 0.940 |
Why?
|
| Urologic Neoplasms | 2 | 2015 | 4 | 0.920 |
Why?
|
| Aged | 20 | 2021 | 8501 | 0.920 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 698 | 0.900 |
Why?
|
| Smokers | 2 | 2023 | 11 | 0.870 |
Why?
|
| Galectin 1 | 3 | 2018 | 4 | 0.860 |
Why?
|
| Prognosis | 11 | 2015 | 739 | 0.850 |
Why?
|
| Kidney Neoplasms | 2 | 2015 | 70 | 0.850 |
Why?
|
| Culturally Competent Care | 1 | 2023 | 10 | 0.840 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 92 | 0.830 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 12 | 0.740 |
Why?
|
| Male | 25 | 2020 | 13917 | 0.740 |
Why?
|
| Female | 26 | 2020 | 14273 | 0.720 |
Why?
|
| Humans | 34 | 2023 | 25692 | 0.720 |
Why?
|
| Middle Aged | 20 | 2018 | 8403 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 70 | 0.650 |
Why?
|
| Immunohistochemistry | 9 | 2015 | 341 | 0.630 |
Why?
|
| Attitude to Health | 1 | 2019 | 90 | 0.620 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 164 | 0.610 |
Why?
|
| Urinary Bladder | 1 | 2018 | 22 | 0.600 |
Why?
|
| Health Status | 1 | 2019 | 209 | 0.590 |
Why?
|
| Mass Screening | 1 | 2018 | 168 | 0.560 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 37 | 0.560 |
Why?
|
| Survivors | 1 | 2017 | 67 | 0.550 |
Why?
|
| Quality of Life | 2 | 2019 | 600 | 0.520 |
Why?
|
| Bisexuality | 2 | 2015 | 7 | 0.520 |
Why?
|
| Homosexuality, Female | 2 | 2015 | 7 | 0.520 |
Why?
|
| Communication | 1 | 2017 | 119 | 0.520 |
Why?
|
| Signal Transduction | 1 | 2018 | 410 | 0.510 |
Why?
|
| Transaminases | 1 | 2015 | 6 | 0.510 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2015 | 1 | 0.500 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2015 | 1 | 0.500 |
Why?
|
| Lipogenesis | 1 | 2015 | 1 | 0.500 |
Why?
|
| Urinary Tract | 1 | 2015 | 2 | 0.490 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 4 | 0.490 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2015 | 1 | 0.490 |
Why?
|
| Group II Phospholipases A2 | 1 | 2015 | 1 | 0.490 |
Why?
|
| Ureteral Neoplasms | 1 | 2015 | 7 | 0.480 |
Why?
|
| Repressor Proteins | 1 | 2015 | 36 | 0.480 |
Why?
|
| Kidney Pelvis | 1 | 2015 | 14 | 0.480 |
Why?
|
| Lipids | 1 | 2015 | 50 | 0.480 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 1 | 0.480 |
Why?
|
| Neoadjuvant Therapy | 4 | 2015 | 59 | 0.470 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 44 | 0.470 |
Why?
|
| Neoplasms | 1 | 2017 | 224 | 0.460 |
Why?
|
| Quality of Health Care | 1 | 2015 | 117 | 0.440 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 132 | 0.430 |
Why?
|
| Adult | 14 | 2019 | 7336 | 0.430 |
Why?
|
| ELAV Proteins | 1 | 2012 | 1 | 0.420 |
Why?
|
| Cyclin A | 1 | 2012 | 3 | 0.420 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2013 | 26 | 0.420 |
Why?
|
| Cytoplasm | 1 | 2012 | 30 | 0.420 |
Why?
|
| Urothelium | 3 | 2018 | 5 | 0.380 |
Why?
|
| Smoking Cessation | 3 | 2019 | 41 | 0.380 |
Why?
|
| United States | 5 | 2023 | 1943 | 0.350 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 4459 | 0.350 |
Why?
|
| Annexin A1 | 1 | 2010 | 1 | 0.340 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 221 | 0.330 |
Why?
|
| Carcinoma | 3 | 2018 | 63 | 0.320 |
Why?
|
| Proteomics | 3 | 2018 | 85 | 0.310 |
Why?
|
| Disease Progression | 5 | 2015 | 664 | 0.310 |
Why?
|
| Chicago | 4 | 2019 | 869 | 0.300 |
Why?
|
| Sexual and Gender Minorities | 2 | 2019 | 23 | 0.290 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 299 | 0.280 |
Why?
|
| Tobacco Use Disorder | 2 | 2019 | 16 | 0.270 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 847 | 0.270 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 157 | 0.260 |
Why?
|
| Taiwan | 4 | 2018 | 7 | 0.250 |
Why?
|
| Minority Groups | 3 | 2015 | 82 | 0.250 |
Why?
|
| Histones | 2 | 2015 | 27 | 0.240 |
Why?
|
| Smoking Prevention | 2 | 2014 | 16 | 0.220 |
Why?
|
| Health Surveys | 2 | 2021 | 85 | 0.210 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 14 | 0.210 |
Why?
|
| Risk Factors | 4 | 2017 | 2224 | 0.210 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 91 | 0.200 |
Why?
|
| Survival Rate | 3 | 2014 | 308 | 0.200 |
Why?
|
| Internet | 1 | 2023 | 93 | 0.190 |
Why?
|
| Psychometrics | 1 | 2023 | 216 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2019 | 3231 | 0.190 |
Why?
|
| Attitude of Health Personnel | 1 | 2023 | 146 | 0.190 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 35 | 0.180 |
Why?
|
| Physicians | 1 | 2023 | 112 | 0.180 |
Why?
|
| Violence | 1 | 2021 | 38 | 0.180 |
Why?
|
| Health Behavior | 2 | 2019 | 136 | 0.180 |
Why?
|
| Blotting, Western | 3 | 2015 | 140 | 0.170 |
Why?
|
| Odds Ratio | 2 | 2018 | 244 | 0.170 |
Why?
|
| Self Efficacy | 1 | 2019 | 53 | 0.160 |
Why?
|
| Age Distribution | 1 | 2019 | 84 | 0.160 |
Why?
|
| Advisory Committees | 1 | 2018 | 19 | 0.160 |
Why?
|
| Lythraceae | 1 | 2018 | 1 | 0.150 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1077 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 9 | 0.150 |
Why?
|
| Plant Extracts | 1 | 2018 | 14 | 0.150 |
Why?
|
| Decision Making | 1 | 2020 | 203 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 37 | 0.150 |
Why?
|
| Educational Status | 1 | 2019 | 271 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 443 | 0.150 |
Why?
|
| Economics, Hospital | 1 | 2017 | 4 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2017 | 35 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2015 | 150 | 0.140 |
Why?
|
| Medicaid | 1 | 2017 | 29 | 0.140 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 20 | 0.140 |
Why?
|
| Age Factors | 1 | 2019 | 716 | 0.140 |
Why?
|
| Sexuality | 2 | 2014 | 14 | 0.140 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 14 | 0.140 |
Why?
|
| Medicare | 1 | 2017 | 107 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 31 | 0.130 |
Why?
|
| Transgender Persons | 2 | 2014 | 20 | 0.130 |
Why?
|
| Gene Expression | 2 | 2016 | 182 | 0.130 |
Why?
|
| Leadership | 1 | 2017 | 97 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 472 | 0.130 |
Why?
|
| Hyaluronan Synthases | 1 | 2015 | 5 | 0.120 |
Why?
|
| Social Discrimination | 1 | 2015 | 2 | 0.120 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 16 | 0.120 |
Why?
|
| Professional-Patient Relations | 1 | 2015 | 25 | 0.120 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2014 | 1 | 0.120 |
Why?
|
| Endosonography | 1 | 2014 | 11 | 0.120 |
Why?
|
| Young Adult | 3 | 2015 | 1855 | 0.120 |
Why?
|
| Independent Living | 1 | 2017 | 294 | 0.120 |
Why?
|
| Social Marketing | 1 | 2014 | 4 | 0.120 |
Why?
|
| Mass Media | 1 | 2014 | 10 | 0.110 |
Why?
|
| Acculturation | 1 | 2014 | 36 | 0.110 |
Why?
|
| Awareness | 1 | 2014 | 42 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2014 | 47 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 198 | 0.110 |
Why?
|
| Obesity | 1 | 2016 | 290 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2014 | 1781 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 87 | 0.110 |
Why?
|
| Health Promotion | 1 | 2014 | 140 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2012 | 18 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2012 | 23 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 128 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2011 | 6 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 143 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 80 | 0.100 |
Why?
|
| 14-3-3 Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Mouth Neoplasms | 1 | 2011 | 20 | 0.090 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2011 | 39 | 0.090 |
Why?
|
| Thrombolytic Therapy | 1 | 2011 | 48 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 53 | 0.090 |
Why?
|
| Casein Kinase II | 1 | 2010 | 2 | 0.090 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2010 | 2 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 104 | 0.090 |
Why?
|
| Cystectomy | 1 | 2010 | 9 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 154 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2010 | 32 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 332 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 315 | 0.060 |
Why?
|
| Dementia | 1 | 2011 | 532 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 277 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 366 | 0.050 |
Why?
|
| Cultural Characteristics | 1 | 2019 | 21 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2019 | 79 | 0.040 |
Why?
|
| Plants, Medicinal | 1 | 2018 | 2 | 0.040 |
Why?
|
| Solvents | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 22 | 0.040 |
Why?
|
| Adolescent | 2 | 2014 | 2076 | 0.040 |
Why?
|
| Acetates | 1 | 2018 | 16 | 0.040 |
Why?
|
| Fruit | 1 | 2018 | 20 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 25 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2018 | 11 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 24 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 98 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 325 | 0.040 |
Why?
|
| Investments | 1 | 2017 | 4 | 0.040 |
Why?
|
| Apoptosis | 1 | 2018 | 177 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2017 | 59 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 23 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 32 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 72 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 110 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 70 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 143 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 167 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 87 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 156 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 1633 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 1336 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 26 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2016 | 211 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 419 | 0.030 |
Why?
|
| Racism | 1 | 2014 | 31 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2014 | 120 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 256 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 66 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2012 | 17 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 32 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 126 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 51 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2011 | 40 | 0.020 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 2011 | 2 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 284 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 26 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 119 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 190 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 3510 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 255 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2011 | 58 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 163 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 131 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 618 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 246 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 532 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 259 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2012 | 3220 | 0.010 |
Why?
|